Orciprenalline

Reading File

Finding Sources

Searching the Web

orciprenalline metaproterenol pharmacology mechanism uses

Reading File

Loading Image

I now have comprehensive textbook content. Here is the full answer:

Orciprenalline (Metaproterenol)

Orciprenalline is the European name for metaproterenol - a moderately selective beta-2 adrenergic agonist bronchodilator. It belongs to the resorcinol structural class and is classified as a short-acting beta-2 agonist (SABA).

Chemical Structure & Class

Orciprenalline is structurally derived from isoproterenol (isoprenaline) but with a key modification: the hydroxyl groups are placed at positions 3 and 5 of the phenyl ring (resorcinol arrangement) instead of the catechol positions 3 and 4. This makes it a resorcinol bronchodilator, along with terbutaline and fenoterol.

Structures of beta-2 agonists including metaproterenol compared to isoproterenol, terbutaline, albuterol, and salmeterol

Structural comparison: note the 3,5-dihydroxy (resorcinol) arrangement in metaproterenol vs the 3,4-catechol in isoproterenol - Katzung's Basic and Clinical Pharmacology

Mechanism of Action

Orciprenalline acts by stimulating beta-2 adrenergic receptors on bronchial smooth muscle, leading to:

Bronchodilation - relaxation of bronchial smooth muscle, decreased airway resistance
Suppression of mediator release (leukotrienes, histamine) from pulmonary mast cells
Enhanced mucociliary clearance
Decreased microvascular permeability
Possible inhibition of phospholipase A2

The beta-2 selectivity is moderate - it is considered less selective than albuterol or terbutaline, making it more prone to cause cardiac stimulation (beta-1 effects) at higher doses.

Goodman & Gilman's Pharmacological Basis of Therapeutics

Pharmacokinetics

The resorcinol modification confers a major pharmacokinetic advantage:

Resistant to COMT methylation (catechol-O-methyl transferase cannot act on it, unlike isoproterenol)
~40% oral bioavailability - a substantial fraction absorbed in active form after oral administration
Not metabolized by MAO to a significant degree
Excreted primarily as glucuronic acid conjugates

Route	Onset	Duration
Inhalation	Within minutes	Several hours (3-4 h)
Oral	Slower (delayed)	3-4 hours
Subcutaneous	Prompt	-

Goodman & Gilman's, Short-Acting beta Adrenergic Agonists section

Therapeutic Uses

Asthma - acute bronchospasm and long-term management of obstructive airway disease
COPD - bronchospasm relief; beta-2 selective drugs including metaproterenol are the preferred agents when administered as inhaled aerosols, especially in patients with cardiac disease
Pulmonary function testing - used as a bronchodilator challenge agent in spirometry to assess reversibility of airflow limitation (a 15-20% improvement in FEV1 indicates reversible obstruction, as in asthma)
Pregnancy - listed as an acceptable beta-2 agonist in pregnant patients with asthma

K.J. Lee's Essential Otolaryngology; Murray & Nadel's Textbook of Respiratory Medicine

Route of Administration

Metered-dose inhaler (MDI) - preferred route; minimizes systemic side effects
Oral tablets/syrup
Nebulized solution
Subcutaneous injection

Inhalation is preferred because it delivers the greatest local bronchial effect with the least systemic toxicity. With aerosol delivery, 80-90% of the dose is deposited in the mouth/pharynx; optimal particles are 2-5 microns, and bronchial deposition is improved by slow inhalation and 5+ seconds of breath-holding.

Adverse Effects

Effect	Mechanism
Tremor (most common)	Beta-2 in skeletal muscle; tolerance develops
Restlessness, apprehension, anxiety	CNS beta effects
Tachycardia / arrhythmia	Beta-1 activation (more so than albuterol) - especially with oral dosing
Hypokalemia	Beta-2 stimulation drives K+ into cells

Patients tend to develop tolerance to tremor over time. The cardiac side effects are more pronounced than with albuterol due to orciprenalline's lower beta-2 selectivity.

Drug Interactions

MAOIs - increase risk of adverse cardiovascular effects; concomitant use should be avoided
Non-selective beta blockers (e.g., propranolol) - diminish or counteract the bronchodilatory effect
At high concentrations, cardiac stimulation becomes more likely due to loss of beta-2 selectivity

Position in Therapy

Orciprenalline/metaproterenol has been largely displaced by more beta-2 selective agents such as albuterol (salbutamol) and terbutaline in most guidelines. Per Goodman & Gilman's, non-selective or less selective short-acting beta agonists like metaproterenol "should only be used as a last resort." Albuterol and levalbuterol are now the SABAs of first choice for acute bronchospasm.

It is not available as an inhaler in some countries (e.g., the US market for inhaled terbutaline is withdrawn; metaproterenol formulations have similarly declined).

Summary Table

Property	Detail
Drug class	Short-acting beta-2 agonist (SABA); resorcinol bronchodilator
Selectivity	Moderate beta-2 selectivity (less than albuterol)
COMT metabolism	Resistant (resorcinol structure)
Oral bioavailability	~40%
Duration of action	3-4 hours
Primary use	Asthma, COPD bronchospasm
Main side effect	Tremor (most common); tachycardia with oral use
Current status	Largely replaced by more selective SABAs (albuterol)

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Illustrated Reviews: Pharmacology; Katzung's Basic and Clinical Pharmacology, 16th ed.; Murray & Nadel's Textbook of Respiratory Medicine

Isoprenaline

Finding Sources

Searching the Web

isoprenaline isoproterenol pharmacology mechanism clinical uses

Reading File

Finding Sources

Reading File

Loading Image

Excellent - I have comprehensive data from multiple top textbooks. Here is the full answer:

Isoprenaline (Isoproterenol)

Isoprenaline (INN) = isoproterenol (USAN). Also known as isopropyl noradrenaline, isopropylterenol, or INE. Brand name: Isuprel. It was the first selective beta-adrenergic receptor agonist ever developed, introduced clinically in 1947.

Chemical Structure & Class

Isoprenaline is a synthetic catecholamine - the N-isopropyl analogue of norepinephrine. Its full chemical name is d,l-β-[3,4-dihydroxyphenyl]-α-isopropylaminoethanol. It has the standard catechol (3,4-dihydroxyphenyl) ring, so it is:

A substrate for COMT - metabolized relatively quickly
A relatively poor substrate for MAO and the norepinephrine transporter (NET), so it is not taken up by sympathetic neurons to the same extent as norepinephrine/epinephrine

The bulky isopropyl group on the nitrogen confers high beta-receptor affinity and markedly reduces alpha-receptor activity.

Receptor Profile

Receptor	Activity
Beta-1	+++ (potent, cardiac)
Beta-2	+++ (potent, vascular/bronchial)
Alpha-1	Essentially none
Alpha-2	Essentially none

It is a potent, non-selective beta agonist with virtually no alpha activity - the defining characteristic that distinguishes it from epinephrine and norepinephrine. Per Guyton & Hall, it has "an extremely strong action on beta receptors but essentially no action on alpha receptors."

Pharmacological Actions

Cardiovascular Effects

The unique receptor profile creates a characteristic hemodynamic pattern:

Cardiovascular effects of intravenous isoproterenol infusion - Lippincott Illustrated Reviews: Pharmacology

Parameter	Effect	Mechanism
Heart rate	↑↑↑ (tachycardia)	Beta-1: positive chronotropy
Myocardial contractility	↑↑↑	Beta-1: positive inotropy
Cardiac output	↑↑	Beta-1 effects
Peripheral vascular resistance	↓↓↓	Beta-2: vasodilation in skeletal muscle, renal, mesenteric, splenic beds
Systolic BP	↑ (slight) or unchanged	Increased cardiac output
Diastolic BP	↓↓ markedly	Peripheral vasodilation
Mean arterial pressure	↓	Net effect dominated by vasodilation
Pulse pressure	Widened	Systolic slightly up, diastolic down

This produces the classic "hyperdynamic" pattern: strong cardiac stimulation + peripheral vasodilation + reduced diastolic BP. The fall in diastolic pressure also means coronary perfusion pressure decreases, which - combined with greatly increased myocardial O2 demand and shortened diastolic filling time - creates significant risk of subendocardial ischemia, even without coronary stenosis.

Bronchial Effects

Potent bronchodilator via beta-2 stimulation of airway smooth muscle
Inhibits antigen-induced release of histamine and other inflammatory mediators from pulmonary mast cells
Relaxes almost all smooth muscle when tone is high, most pronounced in bronchial and GI smooth muscle

Other Effects

Relaxes uterine smooth muscle (tocolytic effect via beta-2)
Causes glycogenolysis and lipolysis
CNS: mild stimulation

Pharmacokinetics

Parameter	Detail
Absorption	Readily absorbed parenterally or by aerosol; poorly absorbed orally
Metabolism	Primarily by COMT in the liver; also in other tissues
MAO metabolism	Relatively poor substrate - not degraded by MAO as efficiently as NE/EPI
Neuronal uptake	Poor substrate for NET; not sequestered in sympathetic neurons
Duration	Relatively brief, but somewhat longer than epinephrine
IV half-life	~2.5 to 5 minutes
IV duration	~10 to 15 minutes

Therapeutic Uses (Current & Historical)

Current / Active Uses

Symptomatic bradyarrhythmias - refractory bradycardia as a bridge while awaiting cardiac pacemaker insertion
AV (heart) block - pharmacological rate support; given as very dilute IV infusion (e.g., 2 mg in 500 mL normal saline)
Torsades de pointes - drug-induced or acquired long QT; isoprenaline increases heart rate and shortens the QT interval, suppressing the arrhythmia
Cardiac transplantation - to increase heart rate and contractility in the denervated donor heart (which lacks autonomic innervation and cannot respond to atropine)

IV dosing: Start infusion at 2 mcg/min, titrate every 5-10 minutes; usual range 2-10 mcg/min (titrated to adequate heart rate).

Historical Uses (Now Largely Replaced)

Former Use	Replaced By
Asthma/bronchospasm	Beta-2 selective SABAs (albuterol, salbutamol)
Cardiogenic shock	Dopamine, dobutamine
Pulmonary hypertension/RV failure	Inhaled NO, prostacyclin (more selective, fewer side effects)
General bronchospasm	Selective beta-2 agonists

In asthma: non-selective beta agonists like isoprenaline "should only be used as a last resort" (Goodman & Gilman's). Its cardiac effects (beta-1) are unwanted when treating airway disease.

Adverse Effects

Effect	Basis
Palpitations, sinus tachycardia	Beta-1 chronotropy
Ventricular arrhythmias (PVCs, VT)	Beta-1 cardiac excitability
Supraventricular tachyarrhythmias	AV nodal acceleration (dromotropic)
Headache, flushing	Peripheral vasodilation
Hypotension	Marked beta-2 vasodilation
Myocardial ischemia / subendocardial necrosis	Increased O2 demand + reduced coronary perfusion pressure + shortened diastolic filling time
Pulmonary edema	With IV use
Dyspnea	Ventilation-perfusion mismatch worsening

Large doses in experimental animals cause myocardial cell death from ischemia.

Contraindications

Angina pectoris / coronary artery disease
Pre-existing tachyarrhythmias or ventricular arrhythmias
Digoxin toxicity (isoprenaline + digoxin increases arrhythmia risk)
Underlying QT prolongation (use with extreme caution; the rate increase is needed for torsades but the drug itself is proarrhythmic in other settings)

Comparison with Related Drugs

Drug	Alpha	Beta-1	Beta-2	Key Use
Isoprenaline	0	+++	+++	Bradycardia, heart block
Epinephrine	+++	+++	+++	Anaphylaxis, cardiac arrest
Norepinephrine	+++	+++	+	Vasopressor (septic shock)
Albuterol	0	+	+++	Asthma (inhaled)
Dobutamine	+/-	+++	+	Cardiogenic shock (inotrope)

Summary

Isoprenaline is a potent, non-selective beta agonist (beta-1 + beta-2) with negligible alpha activity. Its cardiovascular signature is: markedly increased heart rate and contractility + peripheral vasodilation + decreased diastolic BP. It has been largely displaced in most of its former uses by more selective agents, but retains a niche role in refractory bradyarrhythmias, AV block, torsades de pointes, and cardiac transplantation. Its proarrhythmic potential and adverse myocardial oxygen supply-demand effects limit its clinical application.

Difference between orciorenalline and isoprenalline

Based on the detailed coverage in our previous two responses, I can answer this directly and comprehensively without additional searches, as all the information is already in our conversation context.

Orciprenalline vs Isoprenaline - Key Differences

1. Chemical Structure

Feature	Orciprenalline (Metaproterenol)	Isoprenaline (Isoproterenol)
Ring type	Resorcinol (OH at positions 3 & 5)	Catechol (OH at positions 3 & 4)
N-substituent	Isopropyl group	Isopropyl group (same)
Class	Resorcinol bronchodilator	Synthetic catecholamine

This single structural difference - the position of the hydroxyl groups on the benzene ring - has profound downstream consequences.

2. Receptor Selectivity (Most Important Difference)

Receptor	Orciprenalline	Isoprenaline
Beta-1	+ (weak)	+++ (potent)
Beta-2	+++ (predominant)	+++ (potent)
Alpha	None	None

Isoprenaline is a non-selective beta agonist - equally potent at both beta-1 and beta-2
Orciprenalline is a moderately selective beta-2 agonist - preferentially acts on bronchial smooth muscle, with less cardiac stimulation
Orciprenalline's selectivity is still less than albuterol or terbutaline

3. Metabolism

Feature	Orciprenalline	Isoprenaline
COMT substrate?	No - resorcinol ring resists COMT methylation	Yes - catechol ring is metabolized by COMT
MAO substrate?	No	Poor substrate (but metabolized more than orciprenalline)
Oral bioavailability	~40% (active fraction absorbed)	Poor orally (destroyed in gut/liver)
Primary metabolites	Glucuronic acid conjugates	O-methylated products (COMT) + conjugates
Duration of action	Longer (3-4 hours)	Shorter (minutes IV; slightly longer than EPI)

This is a key pharmacokinetic distinction: because orciprenalline is not a catechol, it escapes COMT degradation and can be given orally with meaningful bioavailability. Isoprenaline cannot.

4. Cardiovascular Effects

Effect	Orciprenalline	Isoprenaline
Heart rate	Mild increase (oral/inhaled doses)	Marked tachycardia
Contractility	Minimal	Strongly increased
Systolic BP	Minimally affected	Slightly increased
Diastolic BP	Minimally affected	Markedly decreased
Peripheral resistance	Mild decrease	Marked decrease
Arrhythmia risk	Lower	Higher
Risk of myocardial ischemia	Low	Significant (increased O2 demand + reduced coronary perfusion)

Isoprenaline's powerful beta-1 action causes the classic "hyperdynamic" pattern: strong cardiac stimulation + vasodilation + widened pulse pressure. Orciprenalline at therapeutic inhaled doses largely avoids this.

5. Routes of Administration

Route	Orciprenalline	Isoprenaline
Inhalation (MDI/nebulizer)	Yes (preferred)	Yes (historical; now rarely)
Oral	Yes (40% bioavailability)	No (poorly absorbed)
IV infusion	Limited	Yes (primary route for cardiac indications)
Sublingual	No	Historically yes (now obsolete)

6. Clinical Uses

Indication	Orciprenalline	Isoprenaline
Asthma/bronchospasm	Yes (but 2nd line to albuterol)	Rarely - last resort only
COPD	Yes	No
Heart block / bradycardia	No	Yes - primary indication
Torsades de pointes	No	Yes
Cardiac transplantation	No	Yes (denervated heart)
Spirometry bronchodilator challenge	Yes	No
Uterine relaxation (tocolysis)	Acceptable in pregnancy	No

7. Adverse Effect Profile

Adverse Effect	Orciprenalline	Isoprenaline
Tremor	Common (most frequent)	Yes
Tachycardia/arrhythmia	Mild (mainly with oral dosing)	Prominent - main limiting toxicity
Myocardial ischemia	Rare	Clinically significant risk
Headache/flushing	Mild	Common (from vasodilation)
Hypotension	Mild	Marked (peripheral vasodilation)

8. Current Clinical Status

	Orciprenalline	Isoprenaline
Primary role today	Largely displaced by albuterol for airway disease	Niche cardiac use (bradycardia, torsades)
Guideline stance	"Last resort" for non-selective use in asthma	Retained for specific arrhythmia indications

One-Line Summary

Orciprenalline is a moderately beta-2 selective, orally active, COMT-resistant bronchodilator used for airway disease. Isoprenaline is a non-selective, potent beta-1 + beta-2 agonist, catecholamine that is used primarily for cardiac indications (bradycardia, heart block, torsades de pointes) due to its powerful chronotropic and dromotropic effects - at the cost of significant cardiac toxicity risk.

The structural difference (resorcinol vs catechol) explains virtually all the pharmacokinetic differences; the receptor selectivity difference explains all the clinical differences.

This is a shared conversation. Sign in to Orris to start your own chat.